Advertisement
Advertisement
U.S. markets close in 2 hours 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ITCI Jan 2023 40.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
23.600.00 (0.00%)
As of 02:44PM EDT. Market open.
Advertisement
Full screen
Previous Close23.60
Open23.60
Bid21.80
Ask23.70
Strike40.00
Expire Date2023-01-20
Day's Range23.60 - 23.60
Contract RangeN/A
Volume21
Open Interest398
  • Motley Fool

    Why Intra-Cellular Therapies Stock Rose 21.4% This Week

    Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.

  • Investor's Business Daily

    Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

    Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

  • Motley Fool

    Why Intra-Cellular Therapies Trounced the S&P 500 Today

    For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December. Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit.

Advertisement
Advertisement